Mouse Igg News Today

Head and neck cancer is the sixth deadliest cancer worldwide. Aside from the commonly known biomarkers, such as EGFR and VEGF, Sino Biological offers a vast range of emerging biomarkers, such as Osteonectin, KLK6, FGFR1, and more.

Induced pluripotent stem cells (iPSC) are a promising avenue by which cellular therapies may be enhanced. They also represent massive potential in drug tests and gene therapies. Sino Biological has a vast range of iPSC cytokines for R&D.

Preparing the nanoscale ultrasound contrast agents (Nano-UCAs) and examine the role of their surface charge in complement activation and phagocytosis. Read more

STAT3 has been shown to be a cancer driver and a modulator of the tumor microenvironment. As such, it has become an attractive target for therapeutic drugs and STAT3 inhibitors are developing rapidly.

In this article, ACROBiosystems discusses COVID-19, specifically omicron recombinants and how this could lead to new, infectious strains emerging.

In this article, ACROBiosystems review some major and minor immunological breast cancer targets. they divide the therapies into three categories and elaborate upon each one.

Wax esters (WE) are neutral lipids that consist of a fatty alcohol esterified to a fatty acid. WE are valuable feedstocks in industry for producing lubricants, coatings, and cosmetics. They can be produced chemically from fossil fuel or plant-derived triacylglycerol. As fossil fuel resources are finite, the synthesis of WE in transgenic plants may serve as an alternative source. As chain length and desaturation of the alcohol and acyl moieties determine the physicochemical properties of WE and t...

Chinese herbal medicine suyin detoxification granule inhibits pyroptosis and epithelial-mesenchymal transition by downregulating mavs/nlrp3

Knockout validation: Confirming antibody specificity

Multiple myeloma is a common hematological malignancy that has its origins in plasma cells. Despite treatment becoming more sophisticated, there is still currently no cure. However, immunotherapy targeting CD38/CD3 is proving to be very promising.